BURLINGTON, North Carolina -- LabCorp has received emergency use authorization from the Food and Drug Administration for its Pixel at home coronavirus test kit. The COVID-19 At Home Test Kit allows ...

BURLINGTON, N.C. (WJZY) — North Carolina-based LabCorp announced Tuesday that it has received an Emergency Use Authorization from the U.S. Food and Drug Administration for at-home COVID-19 test kits.

The FDA has authorized the first diagnostic test with a home collection option for COVID-19, the disease caused by coronavirus. In a statement released Tuesday, the FDA said that it had reissued an ...

On March 13, 2020, the day of President Donald Trump's Rose Garden press conference declaring COVID-19 a national emergency, his decision to rely on Labcorp and Quest Diagnostics for the bulk of the ...

North Carolina’s LabCorp has gotten the federal go-ahead for an at-home testing kit for COVID-19, the new coronavirus. It’s the first authorized by the Food and Drug Administration. LabCorp of ...

Laboratory Corporation of America Holdings or Labcorp LH is entangled in the current economic uncertainty due to a challenging volume environment for testing laboratories and utilization weaknesses.

Shares of Laboratory Corporation of America Holdings LH were down about 2.9% in premarket trading on Thursday after the diagnostics company reported lower-than-expected revenue in the fourth quarter ...

March 5 (Reuters) - Diagnostics company Laboratory Corp of America Holdings said on Thursday it will make its coronavirus test available for ordering by healthcare providers from 6 p.m. ET, as the U.S ...

Mark Brown witnessed the birth of modern diagnostic testing from the back seat of his mother's station wagon. He just doesn't remember it, because he was a newborn himself. Mark’s father, Paul Brown, ...

Shares of Labcorp tumbled 4.7% in premarket trading on Thursday after the diagnostics company said revenue in the third quarter of 2022 came in lower than expected as fewer people got PCR or antigen ...

LabCorp LH remained on the pandemic seesaw in the first quarter, as quarterly COVID-19 test revenue fell 18% year over year, and nonpandemic diagnostic revenue rose 14%. This made the 5% decline in ...